宝济药业-B(02659)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02659 宝济药业-B

已收盘 11-04 16:08:09

8.070

+0.335

+4.33%

最高8.145	最低7.680	成交量37.86万
今开7.890	昨收7.735	日振幅6.01%
总市值26.07亿	流通市值12.27亿	总股本3.23亿
成交额300.84万	换手率0.25%	流通股本1.52亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02659","market":"HK","secType":"STK","nameCN":"宝济药业-B","latestPrice":8.07,"timestamp":1793779689110,"preClose":7.735,"halted":0,"volume":378600,"delay":0,"changeRate":0.043309631544925654,"floatShares":152000000,"shares":323000000,"eps":-1.5990929705215418,"marketStatus":"已收盘","change":0.335,"latestTime":"11-04 16:08:09","open":7.89,"high":8.145,"low":7.68,"amount":3008412,"amplitude":0.060116,"askPrice":8.07,"askSize":31900,"bidPrice":7.945,"bidSize":900,"shortable":0,"etf":0,"ttmEps":-1.3913519807923167,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793842200000},"marketStatusCode":5,"adr":0,"listingDate":1765296000000,"exchange":"SEHK","adjPreClose":7.735,"openAndCloseTimeList":[[1793755800000,1793764800000],[1793768400000,1793779200000]],"volumeRatio":0.466153,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02659","defaultTab":"news","newsList":[{"id":"1138884649","title":"宝济药业-B更新10月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1138884649","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138884649?lang=zh_cn&edition=full","pubTime":"2026-11-02 17:04","pubTimestamp":1793610283,"startTime":"0","endTime":"0","summary":"上海宝济药业股份有限公司股票代码02659于2026年11月2日发布10月股份变动月报表。报告显示，截至2026年10月31日，公司已发行股份与注册股本保持不变，整体股本结构无新增发行、购回或注销活动。公告显示，普通股H股方面，截至2026年10月末总数为154,327,250股，其中已发行股份151,535,850股，库存股份2,791,400股，与上月保持一致；普通股其他类别（内资股）为171,654,215股，亦无变化。据悉，公告由执行董事刘彦君签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678466156","title":"董事会主席刘彦君三日合计增持宝济药业-B(02659)26.33万股 涉资约202.43万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2678466156","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678466156?lang=zh_cn&edition=full","pubTime":"2026-10-28 18:43","pubTimestamp":1793184181,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，10月23日、26日、27日，董事会主席刘彦君合计增持宝济药业-B(02659)26.33万股，总金额约为202.43万港元。增持后最新持股数目约为2647.02万股，最新持股比例为17.15%。本交易涉及其他关联方：王征","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1514359.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678435919","title":"港股异动 | 宝济药业-B(02659.HK)涨近6% 获董事会主席刘彦君增持公司股份 BJ045注射液临床试验申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2678435919","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678435919?lang=zh_cn&edition=full","pubTime":"2026-10-28 10:14","pubTimestamp":1793153688,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678220431","title":"董事会主席刘彦君增持宝济药业-B(02659.HK)10.21万股 每股作价约7.44港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2678220431","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678220431?lang=zh_cn&edition=full","pubTime":"2026-10-27 17:24","pubTimestamp":1793093086,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116061405","title":"宝济药业-B（02659）：BJ045注射液获批开展中国临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1116061405","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116061405?lang=zh_cn&edition=full","pubTime":"2026-10-20 18:05","pubTimestamp":1792490731,"startTime":"0","endTime":"0","summary":"2026年10月20日，宝济药业-B发布自愿公告称，公司自主研发的BJ045注射液已于2026年10月19日获中国国家药品监督管理局批准开展临床试验。公告显示，BJ045是一款皮下给药的抗IgG降解酶降解的抗CD20单克隆抗体，可与公司自研IgG降解酶KJ103联合用于治疗中重度自身免疫性疾病。宝济药业-B提示，BJ045的研发和商业化仍存在不确定性，临床试验结果及进度将受到多重因素影响，投资者在买卖公司股份时应保持审慎。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673041070","title":"港股异动 | 宝济药业-B(02659)早盘涨超15% 公司创新管线临床研究和商业化进展顺利","url":"https://stock-news.laohu8.com/highlight/detail?id=2673041070","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673041070?lang=zh_cn&edition=full","pubTime":"2026-10-08 09:49","pubTimestamp":1791424176,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，宝济药业-B早盘涨超15%。截至发稿，涨8.10%，报12.55港元，成交额738.47万港元。消息面上，宝济药业核心产品临床研究和商业化逐步推进。KJ017于2026年3月在国内获批上市，用于辅助皮下输液，并在《欧洲药剂学与生物药剂学杂志》发表两项临床3期研究数据；公司持续拓展合作，截至2026年中报，已经有超过60家合作伙伴使用KJ017用于产品开发，项目涵盖从早期研究到临床开发等不同阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1504440.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02659","BK1161","BK4585","KCAI","VXUS","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116988412","title":"宝济药业-B 9月股份变动月报：股本总体保持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1116988412","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116988412?lang=zh_cn&edition=full","pubTime":"2026-10-02 16:46","pubTimestamp":1790930818,"startTime":"0","endTime":"0","summary":"上海宝济药业股份有限公司于2026年10月2日发布截至2026年9月30日止月份的股份变动月报表。报告显示，公司在本期内整体股本无新增发行或注销活动，股本规模维持稳定。当月，宝济药业-B对H股进行了股份回购操作，累计回购873,700股并作为库存股份持有。此外，报告未显示公司在本月内存在股份期权或股权激励计划方面的授出、行使或失效情况。公司表示，将继续确保满足香港联合交易所有限公司上市规则及相关法律法规的要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168868283","title":"宝济药业-B 2026年中期财报：营收9.88百万元，同比下降76.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1168868283","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168868283?lang=zh_cn&edition=full","pubTime":"2026-09-23 18:18","pubTimestamp":1790158696,"startTime":"0","endTime":"0","summary":"宝济药业-B披露的2026年中期财报显示，截至2026年6月30日止六个月实现营收约9.88百万元，同比2025年同期的约42百万元下降76.5%。报告期内，公司毛利约9.34百万元，毛利率为94.56%，较上年同期的99.37%小幅下降。财报显示，报告期内销售材料收入为1.17百万元，较上年同期的0.98百万元有所增长。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"宝济药业-B 2026年中期财报：营收9.88百万元，同比下降76.5%","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669349711","title":"宝济药业-B盘中涨超10% 核心产品临床研究和商业化逐步推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2669349711","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669349711?lang=zh_cn&edition=full","pubTime":"2026-09-21 11:47","pubTimestamp":1789962420,"startTime":"0","endTime":"0","summary":"模拟交易客户端宝济药业-B盘中涨超10%。截至发稿，股价上涨5.56%，现报14.63港元，成交额1216.14万港元。上半年，宝济药业迎来商业化落地的丰收期，公司正式驶入商业化与国际化双轮驱动的快车道。SJ02自上市以来，在合作伙伴的市场推广下，已经在中国境内29个省完成线上采购平台挂牌及市场准入工作，覆盖超过70家医疗机构。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-21/doc-inisqeue5923262.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669131602","title":"港股异动 | 宝济药业-B(02659.HK)早盘涨超9% 核心产品临床研究和商业化逐步推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2669131602","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669131602?lang=zh_cn&edition=full","pubTime":"2026-09-21 10:58","pubTimestamp":1789959538,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665212523","title":"宝济药业－Ｂ(02659.HK)9月8日耗资137.36万港元回购8.58万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2665212523","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665212523?lang=zh_cn&edition=full","pubTime":"2026-09-08 18:07","pubTimestamp":1788862023,"startTime":"0","endTime":"0","summary":"格隆汇9月8日丨宝济药业－Ｂ(02659.HK)公告，9月8日耗资137.36万港元回购8.58万股，每股回购价格15.81-16.45港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260908/32363640.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192181152","title":"宝济药业-B 9月8日回购8.58万股股份，涉资约137.36万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1192181152","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192181152?lang=zh_cn&edition=full","pubTime":"2026-09-08 17:46","pubTimestamp":1788860804,"startTime":"0","endTime":"0","summary":"上海宝济药业股份有限公司于2026年9月8日发布翌日披露报表，宣布在香港联交所回购股份。公告显示，公司当日回购8.58万股普通股H股，占回购前公司已发行股本约0.05659%，每股回购价格介乎港币15.81元至16.45元，合计支付约137.36万港元。本次回购完成后，公司已发行股份为151,535,850股，库藏股数增加至2,791,400股，公司已发行股份总数仍为154,327,250股。公司同时确认已遵守相关上市规则及其他法律法规的各项规定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宝济药业-B 9月8日回购8.58万股股份，涉资约137.36万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172880699","title":"宝济药业-B回购124,900股股份，耗资约199.57万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1172880699","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172880699?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:51","pubTimestamp":1788774681,"startTime":"0","endTime":"0","summary":"上海宝济药业股份有限公司于2026年9月7日发布翌日披露报表。公司根据回购授权进行股份购回操作，当日于香港联交所场内回购普通股H股124,900股，约占回购前已发行股份总数的0.08231%。根据公告，本次回购每股最高价格为15.72港元，最低价格为16.34港元，合计耗资约199.57万港元。回购完成后，公司已发行股份总数仍为154,327,250股，其中不包括库藏股的已发行股份为151,621,650股，库藏股数量增加至2,705,600股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宝济药业-B回购124,900股股份，耗资约199.57万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665315863","title":"宝济药业-B(02659)9月7日斥资199.57万港元回购12.49万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2665315863","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665315863?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:51","pubTimestamp":1788774667,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宝济药业-B(02659)发布公告，该公司于2026年9月7日斥资199.57万港元回购12.49万股股份，每股回购价格为15.72-16.34港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492853.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119009688","title":"宝济药业-B：9月4日回购18.34万股，耗资约299.31万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1119009688","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119009688?lang=zh_cn&edition=full","pubTime":"2026-09-04 18:21","pubTimestamp":1788517297,"startTime":"0","endTime":"0","summary":"上海宝济药业股份有限公司于2026年9月4日公告，进行股份回购操作。根据披露，本次回购股份数量为183,400股，占回购前已发行股本约0.12071%，回购价格区间为每股15.92港元至16.9港元，合计耗资约299.31万港元。公司购回授权于2026年5月26日获得通过，可根据该授权回购最多15,432,725股，至今已累计回购2,580,700股。公司确认本次回购事宜符合香港联合交易所有限公司证券上市规则及相关法例的规定，已获董事会正式批准并履行必要程序。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宝济药业-B：9月4日回购18.34万股，耗资约299.31万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139013431","title":"宝济药业-B 9月3日回购24.09万股股份，耗资约399.14万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1139013431","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139013431?lang=zh_cn&edition=full","pubTime":"2026-09-03 20:06","pubTimestamp":1788437171,"startTime":"0","endTime":"0","summary":"上海宝济药业股份有限公司2026年9月3日公告显示，公司于当日于香港联交所场内回购股票24.09万股，占回购前公司已发行股本的0.15831%。最高回购价每股17.12港元，最低回购价每股16.15港元，总耗资约399.14万港元。此次交易完成后，公司已发行股本为151,929,950股，库藏股为2,397,300股，合计股本总数仍为154,327,250股。截至目前，已根据该授权在包括香港联交所在内的证券交易所合计回购股份2,397,300股，占授权通过当日已发行股本的1.55339%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宝济药业-B 9月3日回购24.09万股股份，耗资约399.14万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664712088","title":"宝济药业-B(02659)9月3日耗资约399.14万港元回购24.09万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2664712088","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664712088?lang=zh_cn&edition=full","pubTime":"2026-09-03 20:01","pubTimestamp":1788436894,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宝济药业-B(02659)公布，2026年9月3日耗资约399.14万港元回购24.09万股股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491739.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148373891","title":"宝济药业-B回购119,500股，总额约199.43万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1148373891","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148373891?lang=zh_cn&edition=full","pubTime":"2026-09-02 17:52","pubTimestamp":1788342748,"startTime":"0","endTime":"0","summary":"宝济药业-B于2026年9月2日发布翌日披露报表。公告显示，公司于同日通过香港联交所场内回购H股普通股119,500股，占当日公司已发行股本约0.07847%。回购价格区间每股16.46港元至16.96港元，共计1,994,328港元，折合约199.43万港元。本次回购完成后，公司已发行股份数为152,170,850股，库藏股增至2,156,400股，总股本154,327,250股。公告同时披露，公司于2026年5月26日曾获得股东大会批准，可回购股份总数为15,432,725股。本次公告由执行董事刘彦君签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宝济药业-B回购119,500股，总额约199.43万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154221701","title":"宝济药业-B发布2026年8月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1154221701","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154221701?lang=zh_cn&edition=full","pubTime":"2026-09-02 16:42","pubTimestamp":1788338535,"startTime":"0","endTime":"0","summary":"上海宝济药业股份有限公司于2026年9月2日披露2026年8月股份变动月报表。报告显示，截至2026年8月31日，公司法定/注册股本保持不变，累计为人民币65,196,293元，其中 H 股法定/注册股本为人民币30,865,450元，内资股法定/注册股本为人民币34,330,843元。H 股数量与上月相同，为154,327,250股；内资股数量仍为171,654,215股。报告期内未有新增发行，亦无股份注销。公司根据股东大会决议于2026年8月31日回购H股184,800股，成交均价为每股港币16.1859元，上述回购股份已被列作公司库存股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170841805","title":"宝济药业-B 9月1日回购119,200股，耗资约199.42万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1170841805","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170841805?lang=zh_cn&edition=full","pubTime":"2026-09-01 18:06","pubTimestamp":1788257174,"startTime":"0","endTime":"0","summary":"宝济药业-B于2026年9月1日发布翌日披露报表，宣布在香港联交所场内回购119,200股H股，占回购前公司已发行股份总数的约0.07821%。本次回购的每股价格介乎每股港币16.48元至16.81元，平均购回价约港币16.7296元，合计斥资约199.42万港元。本次回购完成后，公司于9月1日的已发行股份数降至152,290,350股，库藏股数增至2,036,900股，总股份数为154,327,250股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宝济药业-B 9月1日回购119,200股，耗资约199.42万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.baopharma.com","stockEarnings":[{"period":"1week","weight":-0.0209},{"period":"1month","weight":-0.3597},{"period":"3month","weight":-0.563},{"period":"6month","weight":-0.6918},{"period":"1year","weight":-0.7068},{"period":"ytd","weight":-0.9003}],"compareEarnings":[{"period":"1week","weight":0.021},{"period":"1month","weight":-0.0186},{"period":"3month","weight":-0.0922},{"period":"6month","weight":-0.1164},{"period":"1year","weight":-0.1006},{"period":"ytd","weight":-0.0821}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海宝济药业股份有限公司是一家主要从事药品研发业务的中国公司。该公司利用合成生物技术开发及提供重组生物药物，专注于攻克治疗选择有限且药物制造工艺复杂的目标病症。该公司聚焦四大领域，包括大容量皮下给药，抗体介导的自身免疫性疾病，辅助生殖药物及以重组生物制药取代传统生化制品的变革性产品。该公司的核心产品包括SJ02（晟诺娃），是一种长效重组人卵泡刺激素羧基末端肽融合蛋白（FSH-CTP），KJ017是一种重组人透明质酸酶，以及KJ103，是一种创新重组免疫球蛋白G(IgG)降解酶。","exchange":"SEHK","name":"宝济药业-B","nameEN":"BAO PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"宝济药业-B(02659)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供宝济药业-B(02659)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"宝济药业-B,02659,宝济药业-B股票,宝济药业-B股票老虎,宝济药业-B股票老虎国际,宝济药业-B行情,宝济药业-B股票行情,宝济药业-B股价,宝济药业-B股市,宝济药业-B股票价格,宝济药业-B股票交易,宝济药业-B股票购买,宝济药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"宝济药业-B(02659)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供宝济药业-B(02659)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}